Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HDV serotonin is an investigational drug developed by Diasome Pharmaceuticals that utilizes hepatic-directed vesicles (HDVs) to deliver serotonin directly to the liver. The technology is designed to target underlying deficiencies contributing to metabolic diseases, particularly type 2 diabetes. By encapsulating serotonin within lipid-based nanoparticles engineered for hepatocyte targeting, the drug aims to modulate glucose metabolism and improve glycemic control in diabetic patients. The approach leverages proprietary delivery systems that enhance uptake by liver cells following oral administration, potentially offering a novel mechanism distinct from traditional antidiabetic therapies[1][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on HDV serotonin.